{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:34:24Z","timestamp":1792092864531,"version":"4.4.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a malignancy of mature, antigen-experienced B lymphocytes. Despite great progress recently achieved in the management of CLL, the disease remains incurable, underscoring the need for further investigation into the underlying pathophysiology. Microenvironmental crosstalk has an established role in CLL pathogenesis and progression. Indeed, the malignant CLL cells are strongly dependent on interactions with other immune and non-immune cell populations that shape a highly orchestrated network, the tumor microenvironment (TME). The composition of the TME, as well as the bidirectional interactions between the malignant clone and the microenvironmental elements have been linked to disease heterogeneity. Mounting evidence implicates T cells present in the TME in the natural history of the CLL as well as in the establishment of certain CLL hallmarks e.g. tumor evasion and immune suppression. CLL is characterized by restrictions in the T cell receptor gene repertoire, T cell oligoclonal expansions, as well as shared T cell receptor clonotypes amongst patients, strongly alluding to selection by restricted antigenic elements of as yet undisclosed identity. Further, the T cells in CLL exhibit a distinctive phenotype with features of \u201cexhaustion\u201d likely as a result of chronic antigenic stimulation. This might be relevant to the fact that, despite increased numbers of oligoclonal T cells in the periphery, these cells are incapable of mounting effective anti-tumor immune responses, a feature perhaps also linked with the elevated numbers of T regulatory subpopulations. Alterations of T cell gene expression profile are associated with defects in both the cytoskeleton and immune synapse formation, and are generally induced by direct contact with the malignant clone. That said, these abnormalities appear to be reversible, which is why therapies targeting the T cell compartment represent a reasonable therapeutic option in CLL. Indeed, novel strategies, including CAR T cell immunotherapy, immune checkpoint blockade and immunomodulation, have come to the spotlight in an attempt to restore the functionality of T cells and enhance targeted cytotoxic activity against the malignant clone.<\/jats:p>","DOI":"10.3389\/fimmu.2020.612244","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T14:46:11Z","timestamp":1611153971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword"],"prefix":"10.3389","volume":"11","author":[{"given":"Elisavet","family":"Vlachonikola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Chatzidimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/hs9.0000000000000334","article-title":"Celebrating 20 Years of IGHV Mutation Analysis in CLL","volume":"4","author":"Chiorazzi","year":"2020","journal-title":"HemaSphere"},{"key":"B4","article-title":"Higher-order connections between stereotyped subsets: Implications for improved patient classification in CLL","volume-title":"Blood","author":"Agathangelidis","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2796.2008.02030.x","article-title":"Microenvironmental influences in chronic lymphocytic leukaemia: The role of antigen stimulation","volume-title":"J Internal Med (J Intern Med)","author":"Ghia","year":"2008"},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. Clinical and Therapeutic Implications","volume":"27","author":"Herishanu","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12918","article-title":"Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia","volume":"99","author":"D\u2019Arena","year":"2017","journal-title":"Eur J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1509317","article-title":"Oxidative stress in chronic lymphocytic leukemia: still a matter of debate","volume":"60","author":"D\u2019Arena","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.145","article-title":"Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles","volume":"23","author":"Plander","year":"2009","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060370","article-title":"A Combination of Cytokines Rescues Highly Purified Leukemic CLL B-Cells from Spontaneous Apoptosis In Vitro","volume":"8","author":"Ghamlouch","year":"2013","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/87720","article-title":"Memory CD8+ T cell differentiation: Initial antigen encounter triggers a developmental program in na\u00efve cells","volume":"2","author":"Kaech","year":"2001","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030167","article-title":"The strategy of T cell antigen-presenting cell encounter in antigen-draining lymph nodes revealed by imaging of initial T cell activation","volume":"198","author":"Baj\u00e9noff","year":"2003","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00213","article-title":"Targeting the immune microenvironment in acute myeloid leukemia: A focus on T cell immunity","volume":"8","author":"Lamble","year":"2018","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86288","article-title":"Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6\u2013deficient process","volume":"1","author":"Patten","year":"2016","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science (80- )"},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000443906","article-title":"Genomic features: Impact on pathogenesis and treatment of chronic lymphocytic leukemia","volume":"39","author":"Tausch","year":"2016","journal-title":"Oncol Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.329","article-title":"The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment","volume":"2017","author":"Gaidano","year":"2017","journal-title":"Hematology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLLpatients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"B26","article-title":"Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines","volume":"9","author":"Gitelson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2015.11.003","article-title":"Tumor microenvironment (TME)-driven immune suppression in B cell malignancy","volume":"1863","author":"Nicholas","year":"2016","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-1632","article-title":"Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia","volume-title":"Clin Cancer Res","author":"Rovida","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000029993","article-title":"Abnormal T-cell function in B-cell chronic lymphocytic leukaemia","volume":"44","author":"Scrivener","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8 +PD-1 + replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0250-6","article-title":"Control of chronic lymphocytic leukemia development by clonally-expanded CD8 + T-cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.1.213","article-title":"Interferon \u03b3 inhibits apoptotic cell death in B cell chronic lymphocytic leukemia","volume":"177","author":"Buschle","year":"1993","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196568","article-title":"Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases","volume":"114","author":"Del Giudice","year":"2009","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2018","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16260","article-title":"Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL","volume":"188","author":"Elston","year":"2020","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.503820","article-title":"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia","volume":"51","author":"Gonzalez-Rodriguez","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04466.x","article-title":"Chronic lymphocytic leukaemia cells drive the global CD4 + T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4 + forkhead box P3 + T cells","volume":"166","author":"Piper","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1330475","article-title":"Regulatory T-cells drive immune dysfunction in CLL","volume":"59","author":"Lad","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/734036","article-title":"Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3","volume":"11","author":"Beyer","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)80856-9","article-title":"Regulatory T Cells: Key Controllers of Immunologic Self-Tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1080\/10428190902803677","article-title":"Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24125","article-title":"FOXP3 expression in tumor cells and implications for cancer progression","volume":"228","author":"Triulzi","year":"2013","journal-title":"J Cell Physiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1479-5876-6-19","article-title":"Foxp3 expression in human cancer cells","volume":"6","author":"Karanikas","year":"2008","journal-title":"J Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2019.01.001","article-title":"FOXP3 and Its Cofactors as Targets of Immunotherapies","volume":"5","author":"Nagai","year":"2019","journal-title":"Engineering"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17845","article-title":"Blockage of FOXP3 transcription factor dimerization and FOXP3\/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor","volume":"8","author":"Lozano","year":"2017","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.298","article-title":"The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia","volume":"11","author":"Yousefi","year":"2015","journal-title":"Futur Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0078091","article-title":"Th17\/IL-17A might play a protective role in chronic lymphocytic leukemia immunity","volume":"8","author":"Hus","year":"2013","journal-title":"PLoS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumor Biol"},{"key":"B54","article-title":"CD28 costimulatory molecule--expression, structure and function","volume":"50","author":"Bo\u0107ko","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.2366","article-title":"In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia","volume":"174","author":"Bonyhadi","year":"2005","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-03858-7_12","article-title":"APC, T cells, and the immune synapse","volume-title":"Curr Top Microbiol Immunol","author":"Reichardt","year":"2010"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2174\/138161212801227023","article-title":"Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy","volume":"18","author":"Riches J","year":"2012","journal-title":"Curr Pharm Des"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936","article-title":"PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901166106","article-title":"E\u03bc- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151100","article-title":"Mellstedt H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70723-9","article-title":"Immunomodulating drugs for chronic lymphocytic leukaemia","volume":"7","author":"Chanan-Khan","year":"2006","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/107327481201900106","article-title":"Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia","volume":"19","author":"Carballido","year":"2012","journal-title":"Cancer Control"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/jci35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro","volume":"119","author":"Blank","year":"2006","journal-title":"Int J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0318-3","article-title":"PI3K\u03b4 inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-412510","article-title":"Coinhibitory molecules in hematologic malignancies: Targets for therapeutic intervention","volume":"120","author":"Norde","year":"2012","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","article-title":"Redefining Chronic Viral Infection","volume":"138","author":"Virgin","year":"2009","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-475939","article-title":"Exhausting T cells in CLL","volume":"121","author":"Zenz","year":"2013","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1660972","article-title":"CD8+ T-cells of CLL-bearing mice acquire a transcriptional program of T-cell activation and exhaustion","volume":"61","author":"Lla\u00f3 Cid","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: A novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22277","article-title":"T cells in chronic lymphocytic leukemia: Can they fight","volume":"8","author":"Vardi","year":"2017","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20122739","article-title":"Clonal expansion in B-CLL: Fungal drivers or self-service","volume":"210","author":"Greaves","year":"2013","journal-title":"J Exp Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.07.011","article-title":"Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells","volume":"4","author":"Os","year":"2013","journal-title":"Cell Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2014.1.125","article-title":"BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma","volume":"2014","author":"Wiestner","year":"2014","journal-title":"Hematology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00005-2","article-title":"Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: A retrospective multicentre study","volume":"1","author":"Baliakas","year":"2014","journal-title":"Lancet Haematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.6.1840","article-title":"Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.2004.04985.x","article-title":"Analysis of IgVH gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery","volume":"126","author":"Degan","year":"2004","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.322","article-title":"Antigen receptor stereotypy in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.3.659","article-title":"Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma","volume":"171","author":"Wen","year":"1990","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.3.1063.415a17_1063_1069","article-title":"Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: Major perturbations are preferentially seen within the CD4 T-cell subset","volume":"94","author":"Rezvany","year":"1999","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.153.9.4281","article-title":"T cell repertoire in patients with B chronic lymphocytic leukemia: Evidence for multiple in vivo T cell clonal expansions","volume":"153","author":"Farace","year":"1994","journal-title":"J Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199809000-00004","article-title":"T-cell clonal expansion in patients with B-cell lymphoproliferative disorders","volume":"21","author":"Alatrakchi","year":"1998","journal-title":"J Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0746","article-title":"Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia","volume":"101","author":"Rezvany","year":"2003","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.111","article-title":"Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL","volume":"25","author":"Hofbauer","year":"2011","journal-title":"Leukemia"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3017","article-title":"Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia","volume":"22","author":"Vardi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.362","article-title":"Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: High-throughput immunoprofiling supports selection by shared antigenic elements","volume":"31","author":"Vardi","year":"2017","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"clincanres.3827.2019","DOI":"10.1158\/1078-0432.CCR-19-3827","article-title":"T cell dynamics in chronic lymphocytic leukemia under different treatment modalities","volume":"26","author":"Vardi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0227","article-title":"HLA-binding properties of tumor neoepitopes in humans","volume":"2","author":"Fritsch","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1011527","article-title":"Antileukemia T-cell responses in CLL \u2013 We don\u2019t need no aberration","volume":"4","author":"Kowalewski","year":"2015","journal-title":"Oncoimmunology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B110","unstructured":"Ibrutinib (Imbruvica): A novel targeted therapy for chronic lymphocytic leukemia ParmarS PatelK Pinilla-IbarzJ 2014"},{"key":"B111","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKI on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015263","article-title":"A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL","volume":"2","author":"Ujjani","year":"2018","journal-title":"Blood Adv"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"De Weerdt","year":"2019","journal-title":"Blood Adv"},{"key":"B118","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/595060","article-title":"Engineered T cells for the adoptive therapy of b-cell chronic lymphocytic leukaemia","volume":"2012","author":"Abken","year":"2012","journal-title":"Adv Hematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected from Activation-induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.5603\/FHC.2011.0023","article-title":"Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia","volume":"49","author":"Giannopoulos","year":"2011","journal-title":"Folia Histochem Cytobiol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"Van Rooij","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T06:49:42Z","timestamp":1697611782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.612244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":125,"alternative-id":["10.3389\/fimmu.2020.612244"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.612244","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"article-number":"612244"}}